JMKX003142
Phase 2Small molecule
JMKX003142 is one of 3 small molecule programs targeting Cardiac Edema. It is currently in Phase 2.
1
Indications
5
Total Trials
5
Active Trials
2
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
2 competitors in Cardiac Edema
#DrugCompanyPhaseTrials
1Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Samsca
OtsukaPhase 3
JMKX003142
JJemincare
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for JMKX003142. EMBL-EBI & Wellcome Sanger Institute.
- [4]